Objectives: Published rates of reintervention after endovascular aneurysm repair (EVAR) range from 10% to 30%. We evaluated a single university center's experience with reinterventions in the context of trial and United States Food and Drug Administration (FDA)-approved devices.
rate) underwent reintervention with a mean aneurysm size of 5.9 6 1.2 cm. The median follow-up was 5 years, with an overall survival of 70.1%. Device specific details are outlined in the Table. Most patients (79.5%) underwent two or fewer reinterventions, 20.5% underwent three, and 7.9% underwent four. For all devices, the most common etiology of reintervention was type II endoleak (52.5%), followed by type I endoleak (18.2%), type III endoleak (9.5%), limb kink (7.3%), iliac occlusive disease (5.8%), endotension (1.5%), and other. The Fig compares etiol ogies between trial and FDA-approved devices. The overall mean time to the first reintervention was 2.3 6 2.5 years, and univariate Cox regression identified male gender (hazard ratio, 1.91; 95% confidence interval [CI] , 1.17-3.10; P ¼ .010) and age at the time of EVAR (hazard ratio, 1.03; 95% CI, 1.01-1.05; P ¼ .006) as risk factors for time to first reintervention. Among all patients requiring reintervention, the mean number of reinterventions for trial devices was significantly greater than that for FDAapproved devices (2.18 vs 1.65; P ¼ .009). Trial devices requiring reintervention had a nearly three-fold increase in odds for the need for greater than two reinterventions (odds ratio, 2.88; 95% CI, 1.12-7.37; P ¼ .031). Trial device, etiology of reintervention, and type of reintervention were not predictive of the need for explant or mortality, but the number of reinterventions was significantly associated with the need for explant (odds ratio, 1.86; 95% CI, 1.17-2.96; P ¼ .009). EVAR device and the need for explant did not impact mortality.
Conclusions: Despite the rigorous nature of patient enrollment in clinical trials and the development of newer iterations of investigational devices, patients undergoing EVAR with trial devices are more likely to undergo a greater number of reinterventions compared to FDAapproved EVARs. Although mortality and the need for explant were not significantly associated with trial devices, the former finding points to an ethical duty to properly inform patients willing to partake in investigational device trials. Only endografts with the option of a 34-to 36-mm proximal diameter were included. Requisite patient demographics, anatomic, and devicerelated variables, and relevant clinical outcomes and imaging were reviewed. The primary outcome in this study was a composite of proximal neck adverse events including type Ia endoleak or stent graft migration >5 mm following EVAR. Outcomes were stratified by device diameter for the large-device cohort (34-36 mm) and the small-device cohort (<34 mm).
Results: A total of 533 patients were treated with EVAR that met the inclusion criteria, and 111 (21.8%) received large-diameter devices. The 30-day and 1-year mortality was 0.94% and 6.75%, respectively. There was no difference between the larger-device cohort vs the smaller-device cohort in 30-day (0.9% vs 0.95%; P ¼ .960) or 1-year mortality (9.0% vs 6.2%; P ¼ .920). Early or delayed type Ia endoleaks occurred in 29 (5.4%) of patients at the latest follow-up. Type Ia endoleaks were more common in the larger device cohort (14 [12.6%]) compared to the smaller device cohort (15 [3.5%]; P <.001). There were 31 (5.8%) stent graft migrations. Graft migration was more common in the larger device cohort (16 [14.4%]) compared to the smaller device cohort (15 [3.5%]; P <.001). After controlling for relevant comorbidities and anatomic variables, larger device diameters were independently associated with the risk of developing proximal neck adverse events (odds ratio, 3.99 [1.75-9.11]).
Conclusions: Standard EVAR in patients with large infrarenal necks requiring a 34-to 36-mm proximal endograft is independently associated with an increased rate of type Ia endoleaks and graft migration. This subset of patients should be considered for more proximal seal strategies with fenestrated or branched devices vs open repair. Also, this group likely needs more stringent radiographic follow-up.
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Long-Term Analysis of Endoleak Onset and Evolution Following Abdominal Aortic Endovascular Repair Using Multiple Grafts
Emiliano Chisci, Azzurra Guidotti, Clara Pigozzi, Enrico Barbanti, Filippo Turini, Patrizia Lo Sapio, Leonardo Ercolini, Stefano Michelagnoli. San Giovanni di Dio Hospital, Florence, Italy Objectives: Endovascular abdominal aortic aneurysm (AAA) repair (EVAR) has an Achilles heel, which is endoleak (EL) presence. This study analyzed EL onset and evolution on long-term period after EVAR using multiple grafts.
Methods: Included were 880 patients (mean age, 75.6 6 8.4 years; 824 male) undergoing EVAR between 1999 and 2015 and with a minimum of 1-year follow-up. Stent grafts implanted included 281 Zenith (32%), 64 AneuRx (7%), 14 Lifepath (2%), 64 Talent (7%), 52 Endurant (6%), 38 Endologix (4%), 164 Excluder (18%), 33 E-Vita (4%), 156 Anaconda (18%), and 14 others (2%). Primary outcomes included allcause mortality and AAA-related mortality. Endoleak onset (ELo) after EVAR was categorized as ELo1 ¼ 0 to 2 years, ELo2 ¼ 2 to 4 years, ELo3 ¼ 4 to 6 years, ELo4 ¼ 6 to 8 years, and ELo5 >8 years. Sac shrinkage/sac expansion and need to reintervention rate were the variables considered for EL evolution. EL diagnosis was made by triphasic computed tomography angiography.
Results: Median follow-up was 48 months (interquartile range, 24-84 months). Survival was 94.5% at 2 years, 74.5% at 6 years, 57.7% at 10 years, and 33.3% at 14 years. Six AAA-related deaths occurred, and two were caused by sac rupture at 1 and 3 years in the presence of type I EL. Freedom from AAA-related-death rate was 99.3% at 14 years. Freedom from EL was 86.4% at 2 years, 81% at 4 years, 79.3% at 6 years, 73.2% at 8 years, 68.3% at 10 years, 62.9% at 12 years, and 48.6% at 14 years. EL rate was 1.9% (n ¼ 19), 16.6% (n ¼ 146), 0.8% (n ¼ 7), and 0.4% (n ¼ 4) for EL type I, II, III, and IV respectively. EL type I, III, and IV onset was similar in all five periods of follow-up. However, for EL type II, Elo1 was 31%, ELo2 was 12.8%, ELo3 was 9.4%, Elo4 was 10.2%, and Elo5 was 11.4% (P < .001). Sac shrinkage occurred in 791 patients (90%), while 89 (10%) had a persistent sac expansion at the last follow-up. Freedom from reintervention was 95.6% at 2 years, 94.1% at 4 years, 90.4% at 6 years, 87.1% at 8 years, 86.4% at 10 years, 82.1% at 12 years, and 80% at 14 years. Of 176 patients, 48 (27.2%) with EL underwent reintervention particularly, 10 (55.6%), 31 (21.2%), 4 (57.1%), and 2 (50%) for EL type I, II, III, and IV, respectively. At multivariate analysis, independent predictors of reintervention were type I EL (odds ratio [OR], 10.8; 95% confidence interval [CI], 1.6-73.2; P ¼ .014), presence of limb stenosis or thrombosis (OR, 65.8; 95% CI, 9.5-454; P < .001), age <65 years (OR, 2.9; 95% CI, 1.1-7.6; P ¼ .03), active smoking (OR, 2.1; 95% CI, 1.1-3.8; P ¼ .02), and sac expansion (OR, 4.9; 95% CI, 1.4-16.8; P ¼ .01). Any statistical difference was seen among stent grafts for any end point.
Conclusions: Our 14-year study shows that EL occurred during the entire follow-up, making long-life surveillance necessary for all EVAR patients. EL evolved to reinterventions in nearly one-third of patients. Aneurysm-related death is very low but associated to the presence of type I EL.
Author Disclosures: E. Barbanti: Nothing to disclose; E. Chisci: Nothing to disclose; L. Ercolini: Nothing to disclose; A. Guidotti: Nothing to disclose; P. Lo Sapio: Nothing to disclose; S. Michelagnoli: Nothing to disclose; C. Pigozzi: Nothing to disclose; F. Turini: Nothing to disclose. Methods: A retrospective analysis (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) of 247 patients who underwent explant (n ¼ 162) or FB-EVAR (n ¼ 85) for failed EVAR was performed. FB-EVAR was performed under a physician-sponsored investigational device exemption. Patient demographics, clinical presentation, failure etiology, perioperative management, and rates of reintervention, morbidity, and mortality were analyzed. Those undergoing surgical explantation were compared to those undergoing FB-EVAR conversion. Statistical analysis included multivariable logistic regressions, Fisher exact, and c 2 tests. Results: The majority of patients were male (216 [87.4%]), with a mean age of 75 years (range, 50-93 years). The mean time period from primary EVAR was higher in FB-EVAR patients (46.42 6 36.86 vs 68.7 6 40.82 months; P < .0001). Graft manufacturer did not differ between those requiring explantation and endovascular conversion (P ¼ .21). The explant group had a higher number of patients requiring urgent/emergent surgery (24 [14.8%] vs 3 [3.5%]; P ¼ .013). No patient with rupture was treated with FB-EVAR but 7.4% (n ¼ 12) of all explants were diagnosed with an aortic rupture. Presence of EVAR graft infection was observed exclusively in explant group (28 [17.3%]). Endoleak was the most common reason for failure in both explant and FB-EVAR groups (74.1% vs 63.5%, respectively; P ¼ .24). Type I endoleak was the most common endoleak reported in both groups occurring more frequently in FB-EVAR patients (63.5% vs 39.5%; P ¼ .0005), while type II endoleak was more common in those undergoing explant (27.2% vs 2.3%; P < .0001). Graft migration (11.7% vs 25.9%; P ¼ .0001) and neck degeneration/disease progression (12.9% vs 58.8%; P < .0001) were more prevalent in those undergoing FB-EVAR, but aneurysm enlargement was more common in explants (67.9% vs 32.9%; P < .0001). The 30-day reintervention rates did not differ between explant and FB-EVAR groups (21% vs 10.6%, respectively; P ¼ .14) nor did 30-day mortality (13% vs 4.7%, respectively; P ¼ .11). A subset analysis excluding emergent/compassionate, infections, and ruptures did not alter the lack of difference in terms of 30-day reinterventions (P ¼ .55) or 30-day mortality (P ¼ .38).
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Outcomes of Explants vs
Conclusions: Explants and FB-EVAR are both necessary options when treating patients with failed EVAR. Different modes of failure may point to a preferred method of treatment, but short-term outcomes are comparable. Clinicians should individualize treatment of
